Oncology

Anthony Letai
Biotech

Dana-Farber oncologist Anthony Letai tapped to direct NCI

Work led by Letai resulted in the development of AbbVie and Roche’s Venclexta (venetoclax), which was first approved by the FDA in 2016 for leukemia.
Darren Incorvaia Sep 30, 2025 5:50am
viking ship long boat chase race water sunset

BioLineRx forges joint cancer venture with Norwegian biotech

Sep 29, 2025 11:22am
reducing people on team

ArsenalBio halves staff amid reorganization efforts

Sep 17, 2025 4:55pm
Servier

Servier hands Ideaya $210M upfront for ex-US rights to PKC asset

Sep 2, 2025 3:02pm
Monoclonal antibody orange red background 3d rendering

Allogene reports patient death tied to mAb in CAR-T pivotal trial

Aug 1, 2025 8:30am
world global globe ex-US country map regions

Roche's Flatiron triples cancer network across 3 countries

Jul 23, 2025 12:20pm
More News

Repare finds suitor for PKMYT1 inhibitor in partner Debiopharm

Jul 16, 2025 5:38am

Turnstone, once allied with AbbVie, accepts $8M Xoma buyout

Jun 27, 2025 9:00am
Fierce Pharma

BioNTech to wind down cell therapy manufacturing in Maryland

Jun 18, 2025 10:23am

Actuate's pancreatic cancer drug boosts survival by 3 months

Jun 2, 2025 7:30am